Clinical uncertainty for the use of rivaroxaban in obesity

J Thromb Haemost. 2021 Mar;19(3):870-871. doi: 10.1111/jth.15200.

Authors

Joshua A Jacobs¹, John J Ryan²

Affiliations

¹ Department of Pharmacy, University of Utah Health, Salt Lake City, UT, USA.
² Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City, UT, USA.

PMID: 33650249
DOI: 10.1111/jth.15200

No abstract available

Publication types

Letter
Comment

MeSH terms

Anticoagulants / adverse effects
Clinical Decision-Making*
Factor Xa Inhibitors / adverse effects
Humans
Obesity / drug therapy
Rivaroxaban* / adverse effects
Uncertainty

Substances

Anticoagulants
Factor Xa Inhibitors
Rivaroxaban